The FDA released approximately 100 warning letters to pharmaceutical companies and telehealth providers, including Novartis and Eli Lilly, demanding changes to drug advertisements deemed misleading. This enforcement follows increased regulatory scrutiny initiated by the Trump administration to ensure accurate risk-benefit communication in drug marketing. Experts question the agency's capacity to monitor follow-up enforcement, highlighting regulatory resource challenges amid staff reductions.